Navigation Links
Ascendis Pharma A/S Announces Presentation at 35th Annual J.P. Morgan Healthcare Conference on January 9
Date:1/3/2017

COPENHAGEN, Denmark, Jan. 3, 2017 /PRNewswire/ -- Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon technology to address significant unmet medical needs in rare diseases, today announced that the company will participate in the 35th Annual J.P. Morgan Healthcare Conference.

Details include:

Event35th Annual J.P. Morgan Healthcare ConferenceLocationThe Westin St. Francis, San FranciscoDateMonday, January 9, 2017Time2:00 p.m. Pacific Time (PT)PresenterJan Mikkelsen, CEO

A live audio webcast of the event will be available in the Investors & News section of the Ascendis Pharma website at www.ascendispharma.com.  A webcast replay will also be available for 30 days.

About Ascendis Pharma A/SAscendis Pharma is applying the TransCon technology platform to build a leading rare disease commercial company. The company utilizes its innovative TransCon technology to address significant unmet medical needs in rare diseases by improving clinically validated parent drugs and creating therapies with potential for best-in-class efficacy, safety and/or convenience.

Ascendis Pharma has a wholly-owned pipeline of rare disease endocrinology programs, including once-weekly TransCon Growth Hormone, which is currently being evaluated in the Phase 3 heiGHt Trial for children with growth hormone deficiency (GHD), TransCon PTH, a long-acting prodrug of parathyroid hormone for hypoparathyroidism, and TransCon CNP, a long-acting prodrug of C-Type Natriuretic Peptide for achondroplasia.  Additionally, Ascendis Pharma has multi-product collaborations with Sanofi in diabetes and Genentech in the field of ophthalmology.

For more information, please visit www.ascendispharma.com.

Forward-Looking Statements This press release contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, included in this press release regarding our future operations, plans and objectives of management are forward-looking statements. Examples of such statements include, but are not limited to, statements relating to (i) our product pipeline, (ii) our ability to apply the TransCon technology platform to build a leading rare disease commercial company, and (iii) our expectations regarding our ability to create therapies with potential for best-in-class efficacy, safety and/or convenience. We may not actually achieve the plans, carry out the intentions or meet the expectations or projections disclosed in the forward-looking statements and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions, expectations and projections disclosed in the forward-looking statements. Various important factors could cause actual results or events to differ materially from the forward-looking statements that we make, including the following: unforeseen safety or efficacy results in our TransCon Growth Hormone, TransCon PTH and TransCon CNP or other development programs; unforeseen expenses related to the development of TransCon Growth Hormone, TransCon PTH and TransCon CNP or other development programs, general and administrative expenses, other research and development expenses and our business generally; delays in the development of TransCon Growth Hormone, TransCon PTH and TransCon CNP or other development programs related to manufacturing, regulatory requirements, speed of patient recruitment or other unforeseen delays; dependence on third party manufacturers to supply study drug; for planned clinical studies; and our ability to obtain additional funding, if needed, to support our business activities. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to our business in general, see our current and future reports filed with, or submitted to, the U.S. Securities and Exchange Commission (SEC), including our Report on Form 6-K filed with the SEC on October 18, 2016. Forward-looking statements do not reflect the potential impact of any future in-licensing, collaborations, acquisitions, mergers, dispositions, joint ventures, or investments we may enter into or make. We do not assume any obligation to update any forward-looking statements, except as required by law.

Internal contact: Investor contact: Media contact:Scott T. Smith  

Patti Bank  

Ami KnoeflerChief Financial Officer  

Westwicke Partners

SparkBioComm(650) 352-8389 

(415) 513-1284

(650) 739-9952ir@ascendispharma.com

patti.bank@westwicke.com

ami@sparkbiocomm.com

 

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/ascendis-pharma-as-announces-presentation-at-35th-annual-jp-morgan-healthcare-conference-on-january-9-300384963.html


'/>"/>
SOURCE Ascendis Pharma A/S
Copyright©2017 PR Newswire.
All rights reserved


Related medicine technology :

1. Ascendis Pharma A/S Reports Third Quarter 2015 Financial Results
2. Ascendis Pharma A/S to Present at the Stifel 2015 Healthcare Conference
3. Ascendis Pharma A/S to Present at Three Upcoming Investor Conferences
4. Ascendis Pharma A/S Reports Second Quarter 2015 Financial Results
5. Ascendis Pharma A/S to Report Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone and Host Conference Call on Thursday, July 30, 2015 at 9:00 a.m. Eastern Time
6. Ascendis Pharma A/S to Present at Upcoming Investor Conferences
7. Ascendis Pharma A/S Announces Results of Phase 1 Study of TransCon Treprostinil
8. Ascendis Pharma A/S Reports Full Year 2014 Financial Results
9. Ascendis Pharma A/S to Report Full Year 2014 Financial Results and Host Conference Call on March 25, 2015
10. Ascendis Pharma to Present at ENDO 2015
11. Ascendis Pharma Announces the Appointment of Thomas P. Soloway as Chief Financial Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/30/2021)... ... March 29, 2021 , ... The University of Texas Health Science Center ... San Antonio Multispecialty and Research Hospital, a destination center for research and treatment of ... In a nod to the COVID-19 pandemic, the ceremony was held virtually. , William ...
(Date:3/30/2021)... ... March 29, 2021 , ... Iora Health ... primary care, has partnered with Devoted Health , one of the fastest-growing ... across Maricopa County and provides seniors with the highest-quality care and experience possible, ...
(Date:3/30/2021)... CITY (PRWEB) , ... March 29, 2021 , ... ... has joined the Vaccine Credential Initiative (VCI), a group bringing together leading health ... record of vaccination status, based on open, interoperable standards. By joining the VCI ...
Breaking Medicine Technology:
(Date:3/30/2021)... , ... March 29, 2021 , ... ... the 21st Century , A Virtual Workshop Presented by WCG FDAnews and Cerulean ... 4:30 pm EDT, https://wcg.swoogo.com/modern-sop-and-quality-systems , Are one’s SOPs written for the ...
(Date:3/30/2021)... ... March 29, 2021 , ... According to data released ... reproductive age (13-44) in need of publicly funded contraception live in counties impacted by ... Colorado’s 64 counties have lost some of their Title X resources. , The ...
(Date:3/30/2021)... ... March 29, 2021 , ... Health Literacy Innovations (HLI), a ... confusion due to low health literacy today announces a new partnership with the ... work with ACAP’s member Safety Net Health Plans, those that provide comprehensive health ...
(Date:3/30/2021)... ... ... Dr. Colin Campbell is proud to announce the 1 year anniversary in their new state ... internal medicine and is a primary care specialist who has been practicing for 23 years. ... keep South Jersey healthy one patient at a time. , “Over the past year, Dr. ...
(Date:3/30/2021)... ... March 30, 2021 , ... The COVID-19 ... and survivors; their families; and their caregivers. Crossroads4Hope is addressing the needs of ... emotional support system, MyGo2Support, which meets needs of people impacted by cancer, no ...
Breaking Medicine News(10 mins):